Novo Nordisk A/S
NVO
$119.78
Closing
▼-0.22%
1D
▲15.79%
YTD
NVO
BBG001S5TSK0
Market cap
$536.99B
52 week high
$148.14
52 week low
$92.94
Volume
517,304
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$536.99B
Analysts' Rating
BUY
Price Target (Mean)
148.92
Total Analysts
4
P/E
40.67
Operating Margin
0.00%
Beta
0.42
Revenue Growth
23.78%
52 week high
$148.14
52 week low
$92.94
Div. Yield
1.21%
EPS Growth
-19.55
Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company’s biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
